Article

Targeting EZH2 Increases Therapeutic Efficacy of Check-Point Blockade in Models of Prostate Cancer

2019-08-08

Abstract excerpt

Prostate cancers are considered immunologically ‘cold’ tumors given the very few patients who respond to checkpoint inhibitor therapy (CPI). Recently, enrichment of interferon (IFN) response genes predicts a favorable response to CPI across various disease sites. The enhancer of zeste homolog-2 (EZH2) is over-expressed in prostate cancer and is known to negatively regulate IFN response genes. Here, we demonstrate...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: e86114a1-921c-51cf-9269-07e7cc20537e
DOI: 10.1101/730135

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Targeting EZH2 Increases Therapeutic Efficacy of Check-Point Blockade in Models of Prostate CancerDOI 10.1101/730135Read

EZH2 as a Prognostic Factor and Its Immune Implication with Molecular Characterization in Prostate Cancer: An Integrated Multi-Omics in Silico AnalysisSemantic proximity Read

EZH2-associated tumor malignancy: A prominent target for cancer treatment.Semantic proximity Read

Targeting Chromatin Effector Pygo2 to Enhance Immunotherapy in Prostate CancerSemantic proximity Read

Multiomics characteristics and immunotherapeutic potential of EZH2 in pan-cancerSemantic proximity Read

A non-canonical EZH2 function sensitizes solid tumors to genotoxic stressSemantic proximity Read

The polycomb group protein EZH2 is involved in progression of prostate cancer.Semantic proximity Read

Overexpression of enhancer of zeste homolog 2 (EZH2) characterizes an aggressive subset of prostate cancers and predicts patient prognosis independently from pre- and postoperatively assessed clinicopathological parametersSemantic proximity Read

Targeting EZH2 Reprograms Intratumoral Regulatory T Cells to Enhance Cancer ImmunitySemantic proximity Read

Lineage-specific canonical and non-canonical activity of EZH2 in advanced prostate cancer subtypesSemantic proximity Read

Tumor-intrinsic PRC2 inactivation drives a context-dependent immune-desert tumor microenvironment and confers resistance to immunotherapySemantic proximity Read

EZH2-TTP-mTORC1 Axis Drives Phenotypic Plasticity and Therapeutic Vulnerability in Lethal Prostate CancerSemantic proximity Read

The correlation of EZH2 expression with the progression and prognosis of hepatocellular carcinomaSemantic proximity Read